Acceptable presentation formats include PowerPoint (.ppt, .pptx), OpenDocument (.opd), or Adobe Acrobat (.pdf). All invited talks will be given in person. A schedule of events for NanoLytica 2025 can ...

An oral presentation will feature ... as the first and only allogeneic CAR T product to show promise in treating solid tumors. The upcoming presentation will share updated data from the Phase ...

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary ...

In a press release, Capsida said the presentations would show new data demonstrating the company’s positive progress across its wholly owned pipeline, proprietary capsid engineering, and manufacturing ...

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with ...

The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment period. A ...

whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.